



PTO/SB/08A (04-07)

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**


(Use as many sheets as necessary)

Sheet 1 of 47

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 09/904,356 |
| Filing Date | July 12, 2001 |
| First Named Inventor | G.P. Allaway et al. |
| Art Unit | 1968 |
| Examiner Name | Jeffery S. Parkin |
| Attorney Docket Number | 43966-CB |

| U. S. PATENT DOCUMENTS | | | | | |
|------------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | | US- 6,258,527 | 07-10-2001 | Littman | |
| | | US- 6,258,782 | 07-10-2001 | Barney et al. | |
| | | US- 6,265,184 | 07-24-2001 | Gary | |
| | | US- 6,268,477 | 06-31-2002 | Gary | |
| | | US- 6,448,375 | 09-10-2002 | Samson | |
| | | US- 6,692,745 | 02-17-2004 | Olson | |
| | | US- 6,692,938 | 02-17-2004 | Samson | |
| | | US- 6,797,811 | 09-28-2004 | Gary | |
| | | US- 6,972,126 | 12-06-2005 | Allaway | |
| | | US- 6,800,447 | 10-05-2004 | Samson | |
| | | US- 5,939,320 | 08-17-1999 | Littman | |
| | | US- 5,817,767 | 10-06-1998 | Allaway | |
| | | US- 6,100,087 | 08-08-2000 | J. Rossi et al. | |
| | | US- 7,175,988 | 02-13-2003 | V. Roschke et al. | |
| | | US- 6,528,625 | 03-04-2003 | L. Wu | |
| | | US- 6,548,636 | 04-15-2003 | T. Draglic | |
| | | US- 7,118,859 | 10-10-2006 | V.M. Litwin et al. | |
| | | US- 7,138,119 | 11-21-2006 | W.C Olson et al. | |
| | | US- 6,930,174 | 08-16-2005 | M. Samson et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|---|----------|--|------------------|---|---|----|
| Examiner Initials* | Cite No. | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T* |
| | | Country Code* Number * Kind Code* (if known) | MM-DD-YYYY | | | |
|  | | WO 97/37005 | 10-27-1997 | | | |
| | | WO 97/28258 | 08-07-1997 | | | |
| | | WO 97/44462 | 11-27-1997 | | | |
| | | WO 01/64710 | 09-07-2001 | | | |
| | | WO 02/068608 | 09-06-2002 | | | |
| | | WO 02/083172 | 10-24-2002 | | | |

Examiner
SignatureDate
Considered

11/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: G.P. Allaway et al.
Serial No.: 09/904,356
Filed: July, 12, 2001
Exhibit A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 47**Complete if Known**

| | |
|------------------------|---------------------|
| Application Number | 09/904,356 |
| Filing Date | July 12, 2001 |
| First Named Inventor | G.P. Allaway et al. |
| Art Unit | 1968 |
| Examiner Name | Jeffery S. Parkin |
| Attorney Docket Number | 43966-CB |

| U. S. PATENT DOCUMENTS | | | | | |
|------------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | | US- 7,151,087 B2 | 12-19-2006 | C. Combadiere et al. | |
| | | US- 7,129,055 | 10-31-2006 | D. Littman et al. | |
| | | US- 7,060,273 | 06-13-2006 | W.C. Olson et al. | |
| | | US- 7,122,185 | 10-17-2006 | W.C. Olson et al. | |
| | | US- 6,908,734 | 06-21-2005 | T. Draglic et al. | |
| | | US- 2002-0068813 A1 | 06-06-2002 | T. Draglic et al. | |
| | | US- 2004-0161739 | 08-19-2004 | M. Samson et al. | |
| | | US- 2004-0110127 | 06-10-2004 | M. Samson et al. | |
| | | US- 2005-0154193 | 07-14-2005 | V. Roschke | |
| | | US- 2003-0166024 | 09-04-2003 | C. Rosen et al. | |
| | | US- 2002-0048786 | 04-25-2002 | C. Rosen et al. | |
| | | US- 2002-0061834 | 05-23-2002 | C. Rosen et al. | |
| | | US- 2003-0166870 | 12-23-2004 | L. Wu et al. | |
| | | US- 2003-0195348 | 10-16-2003 | C. Combadiere | |
| | | US- 2003-0003440 | 01-02-2003 | L. Lopaico | |
| | | US- 2003-0092632 | 05-15-2003 | T. Draglic | |
| | | US- 2007-0026441 A1 | 02-01-2007 | W.C. Olson et al. | |
| | | US- 2004-0062767 | 04-01-2004 | W.C. Olson et al. | |
| | | US- 2003-0139571 A1 | 07-24-2003 | T. Draglic et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|---|----------|---|------------------|---|---|----------------|
| Examiner Initials* | Cite No. | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | MM-DD-YYYY | | | |
|  | | WO 02/22077 | 03-21-2002 | | | |
| | | WO 03/072766 | 09-04-2003 | | | |
| | | WO 07/014114 | 02-01-2007 | | | |
| | | WO 97/47318 A | 12-18-1997 | | | |
| | | WO 98/18826 | 05-07-1998 | | | |
| | | WO 02/064612 | 08-22-2002 | | | |

| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 11/12/2007 |
|--------------------|--|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 3 of 47 | Attorney Docket Number | 43966-CB | |

| U. S. PATENT DOCUMENTS | | | | | |
|------------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | | US- 10/081,128 | 02-22-2002 | W.C. Olson et al. | |
| | | US- 09/212,793 | 12-16-1998 | W.C. Olson et al. | |
| | | US- 08/663,616 | 06-14-1996 | G.P. Allaway | |
| | | US- 08/673,682 | 06-25-1998 | G.P. Allaway | |
| | | US- 08/874,570 | 06-13-1997 | G.P. Allaway | |
| | | US- 08/874,618 | 06-13-1997 | G.P. Allaway | |
| | | US- 09/118,415 | 07-17-1998 | V.M. Litwin | |
| | | US- 60/358,886 | 02-22-2002 | W.C. Olson et al. | |
| | | US- 60/017,157 | 05-20-1996 | D. Littman et al. | |
| | | US- 60/266,738 | 02-06-2001 | W.C. Olson et al. | |
| | | US- 60/282,380 | 04-06-2001 | W.C. Olson et al. | |
| | | US- 60/019,715 | 06-14-1996 | W.C. Olson et al. | |
| | | US- 60/019,941 | 06-14-1996 | G.P. Allaway et al. | |
| | | US- 60/112,532 | 12-16-1998 | W.C. Olson et al. | |
| | | US- 60/185,667 | 02-29-2000 | T. Dragic et al. | |
| | | US- 60/205,839 | 05-19-2000 | T. Dragic et al. | |
| | | US- 60/267,231 | 02-07-2001 | T. Dragic et al. | |
| | | US- 60/272,203 | 02-18-2001 | T. Dragic | |
| | | US- 60/018,508 | 05-28-1996 | C. Combadiere et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|---|-----------------------|---|------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁴ |
| | | Country Code ³ Number ¹ Kind Code ² (if known) | MM-DD-YYYY | | | |
|  | | WO 01/55439 | 08-02-2001 | | | |
| | | WO 01/58915 | 08-16-2001 | | | |
| | | WO 01/58916 | 08-16-2001 | | | |
| | | WO 97/22698 | 06-26-1997 | | | |
| | | WO 97/44055 | 11-27-1997 | | | |
| | | WO 97/032019 | 09-04-1997 | | | |

| | | |
|-----------------------|--------------------|------------|
| Examiner Signature | Date Considered | 11/12/2007 |
|-----------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| | | | |
|-------|---|----|----|
| Sheet | 4 | of | 47 |
|-------|---|----|----|

Complete if Known


| | |
|------------------------|-------------------|
| Application Number | 09/904,356 |
| Filing Date | July 12, 2001 |
| First Named Inventor | G.P. Allaway |
| Art Unit | 1648 |
| Examiner Name | Jeffery S. Parkin |
| Attorney Docket Number | 43966-CB |

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ^o |
|-----------------------|-------------|---|---------------------|--|---|----------------|
| | | Country Code* Number* Kind Code* (if known) | MM-DD-YYYY | | | |
| 2 ↓ | | EP 9687002 B1 | 03-01-1996 | | | |
| | | EP 0883667 B1 | 10-27-2004 | | | |
| | | EP 9687010 B1 | 08-06-1996 | | | |
| | | EP 1145724 A2 | 10-17-2001 | | | |
| | | EP 1146086 A2 | 10-17-2001 | | | |
| | | EP 1146122 A2 | 10-17-2001 | | | |

| | | | |
|-----------------------|---|--------------------|------------|
| Examiner Signature |  | Date Considered | 11/12/2007 |
|-----------------------|---|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

| | | | |
|-------|---|----|----|
| Sheet | 6 | of | 47 |
|-------|---|----|----|

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 09/904,356 |
| Filing Date | July 12, 2001 |
| First Named Inventor | G.P. Allaway |
| Art Unit | 1648 |
| Examiner Name | Jeffery S. Parkin |
| Attorney Docket Number | 43966-CB |

U. S. PATENT DOCUMENTS

[illegible]**FOREIGN PATENT DOCUMENTS**[illegible]

**Examiner
Signature**

Date Considered

| | | |
|----|----|------|
| 11 | 12 | 2007 |
|----|----|------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|-------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 7 | of 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| J | | PCT International Search Report issued June 9, 1997 for International Application Publication No. WO 97/26009 | |
| | | PCT International Search Report issued July 5, 1997 for International Application Publication No. WO 98/56421 | |
| | | PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47319 | |
| | | PCT International Search Report issued September 12, 1998 for International Application Publication No. WO 98/56421 | |
| | | PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47318 | |
| | | PCT International Search Report issued June 7, 2000 for International Application Publication No. WO 00/35409 | |
| | | PCT International Search Report issued August 13, 2003 for International Application Publication No. WO 03/072766 | |
| | | PCT International Search Report issued April 23, 2002 for International Application Publication No. WO 02/22077 | |
| | | PCT International Search Report issued July 31, 2003 for International Application Publication No. WO 02/083172 | |
| | | PCT International Preliminary Examination Report issued January 27, 2000 for International Application Publication No. WO 98/56421 | |

| | | |
|--------------------|-----------------|-----------|
| Examiner Signature | Date Considered | 6/12/2007 |
|--------------------|-----------------|-----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|-------|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete If Known | |
| | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 8 | of 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| 8 | | PCT International Preliminary Examination Report issued July 10, 1998 for International Application Publication No. WO 97/37005 | |
| | | PCT International Preliminary Examination Report issued October 16, 1999 for International Application Publication No. WO 97/47319 | |
| | | PCT International Preliminary Examination Report issued September 28, 2005 for International Application Publication No. WO 03/072766 | |
| | | PCT International Preliminary Examination Report issued April 5, 2006 for International Application Publication No. WO 03/072766 | |
| | | PCT International Preliminary Examination Report issued February 15, 2001 for International Application Publication No. WO 00/35409 | |
| | | PCT International Preliminary Examination Report issued December 24, 2003 for International Application Publication No. WO 02/083172 | |
| | | PCT Written Opinion issued May 25, 2005 in connection with International Application Publication No. WO 03/072766 | |
| | | European Supplementary Partial Search Report issued September 27, 2004 for European Application No. 99966466 | |
| | | European Supplementary Partial Search Report issued February 19, 2003 for European Patent Application No. 98931261.6 | |
| ✓ | | European Supplementary Partial Search Report issued August 26, 2004 for European Patent Application No. 97930120.7 | |

| | | |
|--------------------|-----------------|------------|
| Examiner Signature | Date Considered | 11/12/2007 |
|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | |
|--|-------|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 9 | of 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| 2 | | European Supplementary Partial Search Report issued November 8, 2004 for European Patent Application No. 97930120.7 | |
| | | European Supplementary Search Report issued April 21, 2006 for European Application No. 03713632.2 | |
| | | European Supplementary Search Report issued March 6, 2002 for European Patent Application No. 97917856.3 | |
| | | European Supplementary Search Report issued April 27, 2006 for European Patent Application No. 01970984.9 | |
| | | April 21, 2006 Supplementary European search report under Article 157(2) (a) in connection with European Application No. 03 713 632.2 | |
| | | February 9, 2004 Office action in connection with U.S. Application Serial No. 10/116,797 | |
| | | European Patent Office Communication issued November 11, 2004 in connection with European Patent Application No. 97930120.7 | |
| | | Genbank Sequence Report, Accession Entry X91492 for H. sapiens Chem13, submitted September 14, 1995 | |
| | | Janeway and Travers (1994). Immunobiology, Current Biology Ltd., San Francisco. Pp. 10:27-10:42 | |
| | | Stryer (1988). Biochemistry, 3rd edition. Pp. 984-988 | |

| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 11/12/2007 |
|--------------------|--|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 10 of 47 | Attorney Docket Number | 43966-CB | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | December 17, 2003 Third Party Observations in connection with European Application No. 97904948.3 | |
| | | February 27, 2004 Third Party Observations in connection with European Application No. 97904948.3 | |
| | | Abaza et al. (1992). Effects Of Amino Acid Substitutions Outside An Antigenic Site On Protein Binding To Monoclonal Antibodies Of Predetermi... J. Prot. Chem, 11(5):433- 443 | |
| | | Alkhatib, et al. (1996). Abstract At 3rd Conference On Retroviruses | |
| | | Alkhatib, G., et al. (1996). CC CKR5: A RANTES, MIP-1a, MIP-1β Receptor As A Fusion Cofactor For Macrophage-Tropic HIV-1. Science, 272:1955-1958 | |
| | | Alkhatib, G., et al. (1997). HIV Co-Receptor Activity Of CCR5 And Its Inhibition By Chemokines: Independence From G Protein Signaling and Importance... Virology, 234:340-348 | |
| | | Allaway, G.P., et al. (1993). Synergistic Inhibition Of HIV-1 Envelope-Mediated Cell Fusion By CD4-Based Molecules In Combination... AIDS Res. Hum. Retroviruses, 9:581-587 | |
| | | Allaway, G.P., (1995). Expression And Characterization Of CD4-IgG2, A Novel Heterotetramer That Neutralizes Primary HIV Type 1... Aids Res. Hum. Retrovirus, 11:533-539 | |
| | | Amara, A., et al. (1997). HIV Coreceptor Downregulation As Antiviral Principle: SDF-La-Dependent Internalization Of The Chemokine Receptor... J. Exp. Med., 186:139-146 | |
| | Arenzana-Selsdedos, F., et al. (1996). HIV Blocked By Chemokine Antagonist. Nature, 383:400 | | |

| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 11/12/2007 |
|--------------------|--|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|-------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 11 of 47 | Attorney Docket Number | 43966-CB | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| J | | Arthos, J., et al. (1989). Identification Of The Residues In Human CD4 Critical For The Binding Of HIV. Cell, 57:469-481 | |
| | | Ashom, P.A., et al. (1990). Human Immunodeficiency Virus Envelope Glycoprotein/CD4 Mediated Fusion Of Nonprimate Cells With Human Cells. J. Virol., 64:2149-2156 | |
| | | Attanasio, et al. (1991). Anti-Idiotypic Antibody Response To Monoclonal Anti-CD4 Preparations in Nonhuman Primate Species. J. Immunol., 146:507-514 | |
| | | Baba, et al. (1998). Mechanism Of Inhibitory Effect Of Dextran Sulfate And Heparin On Replication Of Human Immunodeficiency Virus In... Proc. Natl. Acad. Sci., 85:6132-6135 | |
| | | Back, D.J. (1999). Pharmacological Issues Relating To Viral Resistance. Infection, 27(Suppl.2):S42-S44 | |
| | | Balzarini, et al. (1995). Suppression Of The Breakthrough Of HIV-1 In Cell Culture By Thiocarboxanilide Derivatives... Proc. Natl. Acad. Sci., 92:5470-5474 | |
| | | Baulerle and Huttner (1987). Tyrosine Sulfation Is A Trans-Golgi-Specific Protein Modification. Cell. Biol., 105:2655-2663 | |
| | | Berger, et al. (1996). Abstract No. 002, 8 at Keystone Symposium | |
| | | Berger E.A. (1997). HIV Entry And Tropism: The Chemokine Receptor Connection. AIDS, 11(Suppl.A):S3-S16 | |
| | | Berger, et al. (1999). Chemokine Receptors As HIV-1 Coreceptors: Roles In Viral Entry, Tropism And Disease. Ann. Rev. Immunol., 17:657-700 | |

| | | |
|--------------------|-----------------|------------|
| Examiner Signature | Date Considered | 11/12/2007 |
|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 12 of 47 | Attorney Docket Number | 43966-CB | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| 2 | | Bleul, C.C., et al. (1991). The Lymphocyte Chemoattractant SDF-1 Is A Ligand For LESTR/Fusion And Blocks HIV-1 Entry. Nature, 382:829-832 | |
| | | Brelot, A., et al. (1997). Role Of The First And Third Extracellular Domains Of CXCR4 In Human Immunodeficiency Virus Coreceptor Activity. J. Virol., 71:4744-4751 | |
| | | Brenner, T.J., et al. (1996). Relation Between HIV-1 Syncytium Inhibition Antibodies And Clinical Outcome In Children. Lancet, 337:1001-1005 | |
| | | Broder, et al. (1993). The Block To HIV-1 Envelope Glycoprotein-Mediated Membrane Fusion In Animal Cells Expressing Human CD4... Virol., 193:483-491 | |
| | | Broder, et al. (1996). HIV And The 7-Transmembrane Domain Receptors. Pathobiology, 64(4):171-179 | |
| | | Burkly, L., et al. (1995). Synergistic Inhibition Of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Cell Fusion and Infection... J. Virol., 69:4267-4273 | |
| | | Burton, D.R., et al. (1994). Efficient Neutralization Of Primary Isolates Of HIV-1 By A Recombinant Human Monoclonal Antibody. Science, 266:1024-1027 | |
| | | Busso, et al. (1991). HIV-Induced Syncytium Formation Requires The Formation Of Conjugates Between Virus-Infected And Uninfected T-Cells In Vitro. AIDS, 5:1425-1432 | |
| | | Cammack, N. (1999). Human Immunodeficiency Virus Type 1 Entry And Chemokine Receptors: A New Therapeutic Target. Antiviral Chemistry And Chemotherapy, 10:53-62 | |
| | | Capon, D.J., et al. (1989). Designing CD4 Immunoadhesions For AIDS Therapy. Nature, 337:525-531 | |


| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 11/12/2002 |
|--------------------|--|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete If Known | |
| | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 13 of 47 | Attorney Docket Number | 43966-CB | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|  | | Chan, D.C., et al. (1998). Evidence That A Prominent Cavity In The Coiled Coil Of HIV Type 1 Gp41 Is An Attractive Drug Target. Proc. Natl. Acad. Sci., 95:15613-15617 | |
| | | Chan, D.C., et al. (1998). HIV Entry And Its Inhibition. Cell, 93:681-684 | |
| | | Charo, et al. (1994). Molecular Cloning And Functional Expression Of Two Monocyte Chemoattractant Protein 1 Receptors Reveals... Proc. Natl. Acad. Sci., 91:2752-2756 | |
| | | Chen, et al. (1997). Genetically Divergent Strains Of Simian Immunodeficiency Virus Use CCR5 As A Coreceptor For Entry. J. Of Virol., 71(4):2705-2714 | |
| | | Choe, H., et al. (1996). The Beta-Chemokine Receptors CCR3 And CCR5 Facilitate Infection By Primary HIV-1 Isolates. Cell, 85:1135-1148 | |
| | | Clapham, P.R., et al. (1991). Specific Cell Surface Requirements For The Infection Of CD4-Positive Cells By Human Immunodeficiency Virus Types 1 And 2... Virol., 181:703-715 | |
| | | Co, et al. (1991). Humanized Antibodies For Antiviral Therapy. Proc. Natl. Acad. Sci., 88:2869-2873 | |
| | | Cocchi, F. (1995). Identification Of RANTES, MIP-1alpha And MIP-1beta As The Major HIV-Suppressive Factors Produced By CD8+ T-Cells. Science, 270:1811-1815 | |
| | | Combadiere, et al. (1995). Cloning And Functional Expression Of A Human... J. Biol. Chem., 270, 16491-16494 (NOTE - Erratum In: J. Biol. Chem. 1995 Dec 15; 270(50):30235)) | |
| | | Combadiere, et al. (1996). Cloning And Functional Expression Of CC CKR5, A Human Monocyte CC Chemokine Receptor Selective For... J. Leukos. Biol., 60:147-152 | |

| | | | |
|--------------------|---|-----------------|-----------|
| Examiner Signature |  | Date Considered | 6/12/2002 |
|--------------------|---|-----------------|-----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 14 of 47 | Attorney Docket Number | | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| J | | Connor, R.I., et al., (1997). Change In Co-Receptor Use Correlates With Disease Progression In HIV-1 Infected Individuals. J. Exp. Med., 185:621-628 | |
| | | Cormier, E.G., et al. (2000). Specific Interaction Of CCR5 Amino-Terminal Domain Peptides Containing Sulfotyrosines With HIV-1 Envelope...Proc. Natl. Acad. Sci., 97:5762-5767 | |
| | | Crump, M.P., et al. (1997). Solution Structure And Basis For Functional Activity Of Stromal-Cell Derived Factor-1: Disassociation Of CXCR4 Activation... EMBO, 16:6996-7007 | |
| | | Cruse, et al. (1995). Illustrated Dictionary Of Immunology, CRC Press, Inc., Boca Raton, FL., 143:QR180.4.C78 | |
| | | Cushman, M., et al. (1991). Preparation And Anti-HIV Activities Of Aurintricarboxylic Acid Fractions And Analogues: Direct Correlation Of... J. Med. Chem., 34:329-337 | |
| | | Daar, E.S. (1990). High Concentrations Of Recombinant Soluble CD4 Are Required To Neutralize Primary Human Immunodeficiency Virus... Proc. Natl. Acad. Sci., 87:6574-6578 | |
| | | Dalglish, A.G., et al. (1984). The CD4 (T4) Antigen Is An Essential Component Of The Receptor For The AIDS Retrovirus. Nature, 312:763-766 | |
| | | Dalglish, A.G. (1995). HIV And CD26. Nature Medicine, 1:881-882 | |
| | | De Rossi, A., et al. (1995). Synthetic Peptides From The Principle Neutralizing Domain Of Human Immunodeficiency Virus Type 1 (HIV-1) Enhance HIV-1... Virology, 184:187-196 | |
| | | Dean, M., et al. (1996). Genetic Restriction Of HIV-1 Infection And Progression To AIDS By A Deletion Allele Of The CKR5 Structural Gene. Science, 273:1856-1862 | |

| | | |
|--------------------|-----------------|------------|
| Examiner Signature | Date Considered | 11/12/2007 |
|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 15 of 47 | Attorney Docket Number | | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | De Clerq, et al. (1992). Potent And Selective Inhibition Of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Replication By A Class Of... Proc. Natl. Acad. Sci., 89:5286-5290 | |
| | | De Clerq, et al. (1994). Highly Potent And Selective Inhibition Of Human Immunodeficiency Virus By The Bicyclam... Antimicrobial Agents and Chemotherapy, 38:668-674 | |
| | | De Clerq, et al. (1995). Antiviral Therapy For Human Immunodeficiency Virus Infections. J. Clin. Microbiol. Rev., 8(2):200-239 | |
| | | Deen, K.C., et al. (1988). A Soluble Form Of CD4(T4) Protein Inhibits AIDS Virus Infection. Nature, 331:82-84 | |
| | | Deng, H., et al. (1996). Identification Of A Major Co-Receptor For Primary Isolates Of HIV-1. Nature, 381:661-666 | |
| | | Deng, X., et al. (1999). A Synthetic Peptide Derived From Human Immunodeficiency Virus Type 1 Gp120 Down-Regulates The Expression And Function... Blood, 94(4):1165-1173 | |
| | | Dettin, et al. (2003). CCR5 N-Terminus Peptides Enhance X4 HIV-1 Infection By CXCR4 Up-Regulation. Biochem. Biophys. Res. Commun., 307(3):640-646 | |
| | | Dikic (1996). Regulation of HIV-1 Infection by Chemokine Receptors. Acta Med. Croatica, 50:163-168 | |
| | | Ditzel, et al. (1998). The CCR5 Receptor Acts As An Alloantigen In CCR5Δ32 Homozygous Individuals: Identification Of Chemokine And... Proc. Natl. Acad. Sci., 95(9):5241-5245 | |
| | | Donzella, G.A., et al. (1998). AMD3100, A Small Molecule Inhibitor Of HIV-1 Entry Via The CXCR4 Co-Receptor. Nat. Med., 4:72-77 | |

| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 11/12/2007 |
|--------------------|--|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 16 of 47 | Attorney Docket Number | 43966-CB | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|  | | Doranz, B.J., et al. (1996). A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin And Beta-Chemokine Receptors CKR-5, CKR-3 And CKR-2b As Fusion Cofactors. Cell, 85:1149-1158 | |
| | | Doranz, B.J., et al. (1997). Two Distinct CCR5 Domains Can Mediate Co-Receptor Usage By Human Immunodeficiency Virus Type 1. J. Virol., 71:6305-6314 | |
| | | Doranz, B.J., et al. (1997). A Small Molecule Inhibitor Directed Against The Chemokine Receptor CXCR4 Prevents Its Use As An HIV-1 Co-Receptor. J. Ex. Med., 186:1395-1400 | |
| | | Dragic, T.V., et al. (1995). Proteinase-Resistant Factors In Human Erythrocyte Membranes Mediated CD-4 Dependent Fusion With Cells Expressing... J. Virol., 69:1013-1018 | |
| | | Dragic, T.V., et al. (1996). HIV-1 Entry Into CD4+Cells Is Mediated By The Chemokine Receptor CC-CKR-5. Nature, 381:667-673 | |
| | | Dragic, T.V., et al. (1998). Amino-Terminal Substitutions In The CCR5 Coreceptor Impair Gp120 Binding And Human Immunodeficiency Virus Type 1 Entry. J. Virol., 72(1):279-285 | |
| | | Dragic, et al. (2000). A Binding Pocket For A Small Molecule Inhibitor Of HIV-1 Entry Within The Transmembrane Helices Of CCR5. Proc. Natl. Acad. Sci., 97(10):5639-5644 | |
| | | Eckert, D.M., et al. (1999). Inhibiting HIV-1 Entry: Discovery Of D-Peptide Inhibitors That Target The gp41 Coiled-Coil Pocket. Cell, 99:103-115 | |
| | | Eugen-Olsen, J., et al. (1997). Heterozygosity For A Deletion In The CKR-5 Gene Leads To Prolonged AIDS-Free Survival And Slower CD4 T-Cell... AIDS, 11:305-310 | |
|  | | Fahey, J.L., et al. (1992). Status Of Immune-Based Therapies In HIV Infection And AIDS. Clin. Exp. Immunol., 88:1-5 | |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 11/12/2007 |
|--------------------|---|-----------------|------------|


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 17 of 47 | Attorney Docket Number | | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|  | | Farzan, M., et al. (1998). A Tyrosine-Rich Region In The N-Terminus Of CCR5 Is Important For Human Immunodeficiency Virus Type 1 Entry And Mediates...J. Virol., 72:1160-1164 | |
| | | Farzan, M., et al. (1999). Tyrosine Sulfation Of The Amino-Terminus Of CCR5 Facilitates HIV-1 Entry. Cell, 96:667-676 | |
| | | Farzan, M., et al. (2000). A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1... J. Biol. Chem., 275:33416-33521 | |
| | | Feng, et al. (1996). Abstract No. 116,21 at Keystone Symposium | |
| | | Feng, Y., et al. (1996). HIV-1 Entry Cofactor: Functional cDNA Cloning Of A Seven-Transmembrane, g Protein-Coupled Receptor. Science, 272:872-877 | |
| | | Ferrer, M., et al. (1999). Selection Of gp-41 Mediated HIV-1 Cell Entry Inhibitors From Biased Combinatorial Libraries Of Non-Natural... Nature. Struct. Biol., 6:953-959 | |
| | | Flexner, C. and Hendrix, C. (1997). "Pharmacology Of Antiretroviral Agents", in AIDS: Bio,... 4th Edition, De Vita V., et al. eds., Lippincott-Raven Publishers. Pp. 479-493 | |
| | | Fouts, T.R., et al. (1997). Neutralization Of The Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL By Human Monoclonal Antibodies... J. Virol., 71:2779-2785 | |
| | | Fox, J.L. (1994). No Winners Against Aids. Bio/Technology, 12:128 | |
| | | Fradd, F. and Mary, M.E. (1989). AIDS Vaccines: An Investor's Guide, Shearman Lehman Hutton. P. 10:(Fig. 2) | |

| | | |
|--------------------|-----------------|-----------|
| Examiner Signature | Date Considered | 4/12/2007 |
|--------------------|-----------------|-----------|


*EXAMINER: Initial if reference considered. Whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 18 of 47 | Attorney Docket Number | 43966-CB | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| J | | Furuta, R.A., et al. (1998). Capture Of An Early Fusion-Active Conformation Of HIV-1 gp41. Nature Struct. Biol., 5(4):276-279 | |
| | | Gait, M.J and Karn, J. (1995). Progress In anti-HIV Structure Based Drug Design. TIBTECH, 13:430-438 | |
| | | Gauduin, M.C., et al. (1996). Effective Ex Vivo Neutralization Of Plasma HIV-1 By Recombinant Immunoglobulin Molecules. J. Virol., 70:2586-2592 | |
| | | Gauduin, M.C., et al. (1997). Passive Immunization With A Human Monoclonal Antibody Protects hu-PBL-SCID Mice Against Challenge By Primary... Nature Medicine, 3:1389-1393 | |
| | | Ghorpade A., et al. (1998). Role Of The Beta-Chemokine Receptors CCR3 And CCR5 In Human Immunodeficiency Virus Type 1 Infection Of Monocytes And.... J. Virol, 72:3351-3361 | |
| | | Golding, H., et al. (1992). LFA-1 Adhesion Molecules Are Not Involved In The Arly Stages Of HIV-1 Env-Mediated Cell Membrane Fusion. AIDS Res. Hum. Retroviruses, 8:1593-1598 | |
| | | Gong, J.H., et al. (1995). Antagonists Of Monocyte Chemoattractant Protein 1 Identified By Modification Of Functionally Critical NH2-Terminal.... J. Exp. Med., 181:631-640 | |
| | | Gong, J.H., et al. (1996). RANTES And MCP-3 Antagonists Bind Multiple Chemokine Receptors. J. Biol. Chem., 371:10521-10527 | |
| | | Grene, et al. (2001). Anti-CCR5 Antibodies In Sera Of HIV-Positive Individuals. Human Immunol., 62(2):143-145 | |
| | | Harrington, R.D. and Geballe, A.P. (1993). Cofactor Requirement For Human Immunodeficiency Virus Type 1 Entry Into A CD4-Expressing Human Cell Line. J. Virol., 67:5939-5947 | |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 11/12/2001 |
|--------------------|---|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 19 of 47 | Attorney Docket Number | 43966-CB | |


| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| 2 | | Hattori, T., et al. (1989). Involvement Of Trypsin-Related Cellular Protease(S) In Human Immunodeficiency Virus Type 1 Infection. FEBS Letters, 248:48-52 | |
| | | Haynes, B.F. (1996). Updates On The Issues Of HIV Vaccine Development. Ann. Med., 28:39-41 | |
| | | He, Jianglin, et al. (1997). CCR3 And CCR5 Are Co-Receptors For HIV-1 Infection Of Microglia. Nature, 385:645-649 | |
| | | Heath, et al. (1997). Chemokine Receptor Usage By Human Eosinophils. The Importance Of CCR3 Demonstrated Using An Antagonistic Monoclonal... J. Clin. Invest., 99:178-184 | |
| | | Heidenreich, et al. (1995). Application Of Antisense Technology To Therapeutics. Mol. Med. Today, 1:128-133 | |
| | | Hildreth, et al. (1989). Involvement Of A Leukocyte Adhesion Receptor (LFA-1) In HIV-Induced Syncytium Formation. Science, 244:1075-1078 | |
| | | Hill, C.M., et al. (1998). The Amino Terminus Of Human CCR5 Is Required For Its Function As A Receptor To Diverse Human And Simian Immunodeficiency... Virology, 248:357-371 | |
| | | Hirata, Y. (1989). Characterization Of IL-6 Receptor Expression By Monoclonal And Polyclonal Antibodies. J. Immun., 2900-2906 | |
| | | Howard, O.M.Z., et al. (1998). Small Molecule Inhibitor Of HIV-1 Cell Fusion Blocks Chemokine Receptor-Mediated Fusion. J. Leuk. Biol., 64:6-13 | |
| | | Hwang, S.S., et al. (1991). Identification Of The Envelope V3 Loop As The Primary Determinant Of Cell Tropism In HIV-1. Science, 253:71-74 | |


| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 11/12/2007 |
|--------------------|--|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 20 of 47 | Attorney Docket Number | 43966-CB | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|  | | Jacobson, J.M., et al. (1993). Passive Immunotherapy In The Treatment Of Advanced Human Immunodeficiency Virus Infection. J. Infect. Dis., 168:298-305 | |
| | | Jacobson, J., et al. (1999). Results Of A Phase..., A Novel Inhibitor Of HIV Entry. Abstracts Of The 39th Interscience Conference On Antimicrobial Agents And Chemotherapy 14 | |
| | | Ji, H., et al. (1999). Inhibition Of Human Immunodeficiency Virus Type 1 Infectivity By The gp41 Core: Role Of A Conserved Hydrophobic Cavity In... J. Virol., 73:8578-8586 | |
| | | Jiang, S., et al. (1993). HIV-1 Inhibition By A Peptide. Nature, 365:113 | |
| | | Jones, S.A., et al. (1997). Chemokine Antagonists That Discriminate Between Interleukin-8 Receptors. J. Biol. Chem., 272:16166-16199 | |
| | | Karwowska, S., et al. (1991). Passive Immunization For The Treatment And Prevention Of HIV Infection. Biotech. Therap., 2:31-48 | |
| | | Katinger, H. (1994). Human Monoclonal Antibodies For Passive Immunotherapy Of HIV-1. Antibiot. Chemother., 46:23-37 | |
| | | Kilby, J.M., et al. (1998). Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry. Nature Med., 4:1302-1307 | |
| | | Klotman, et al. (1995). Transgenic Models Of HIV-1. AIDS, 9(4):313-324 | |
| | | Konigs, C., et al. (2000). Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine... Eur. J. Immunol., 30(4):1162-1171 | |

| | |
|--|---------------------------|
| Examiner Signature  | Date Considered 6/12/2007 |
|--|---------------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|--------------------------|-------------------|------------------------|----------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete If Known | | | |
| | | Application Number | 09/904,356 | | |
| | | Filing Date | July 12, 2001 | | |
| | | First Named Inventor | G.P. Allaway | | |
| | | Art Unit | 1648 | | |
| | | Examiner Name | Jeffery S. Parkin | | |
| Sheet | 21 | of | 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| ✓ | | Konishi, K., et al. (2000). Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1... Chem. Pharm. Bull., Tokyo, 48(2):308-309 | |
| | | Koup, R.A., et al. (1996). Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice. Immunology, 8:263-268. | |
| | | Kwong, P.D. et al. (1998). Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing Human Antibody. Nature, 393:648-659 | |
| | | Laal, S., et al. (1994). Synergistic Neutralization Of Human Immunodeficiency Virus Type 1 By Combinations Of Human Monoclonal Antibodies. J. Virol., 68:4001-4008 | |
| | | LaCasse, R.A., et al. (1999). Fusion-Competent Vaccines: Broad Neutralization Of Primary Isolates Of HIV. Science, 283:357-362 | |
| | | Lee, B., et al. (1999). Epitope Mapping Of CCR5 Reveals Multiple Conformational States And Distinct But Overlapping Structures Involved In... J. Biol. Chem., 9617-9626 | |
| | | Lehner, et al. (2001). Immunogenicity Of The Extracellular Domains Of C-C Chemokine Receptor 5 And The In Vitro Effects On Simian... Journal Of Immunology, 166(12):7446-7455 | |
| | | Levy, J.A. (1996). Controlling HIV Pathogenesis: The Role Of The Non-Cytotoxic Anti-HIV Response Of CD8+ Cells. Immunology Today, 17:217-224 | |
| | | Li, A., et al. (1997). Synergistic Neutralization Of Chimeric SIV/HIV Type 1 Virus With Combinations Of Human Anti-HIV Type 1... AIDS Res. Hum. Retroviruses, 12:647-56 | |
| | | Li, A.H., et al. (1998). Synergistic Neutralization Of Simian-Human Immunodeficiency Virus SHIV-vpu+ By Triple And Quadruple Combination Of Human... J. Virol., 72:3235-3240 | |

| | | | |
|-----------------------|---|--------------------|------------|
| Examiner Signature |  | Date Considered | 11/12/2007 |
|-----------------------|---|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1448/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 22 of 47 | Attorney Docket Number | 43966-CB | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | Litwin, V.M., et al. (1996). Human Immunodeficiency Virus Type 1 Membrane Fusion Mediated By A Laboratory-Adapted Strain And A Primary Isolate..., J. Virol., 70(9):6437-6441 | |
| | | Loetscher, M., et al. (1994). Cloning Of A Human Seven-Transmembrane Domain Receptor, LESTR, That Is Highly Expressed In Leukocytes. J. Biol. Chem., 269:232-237 | |
| | | Mack, M., et al. (1998). Aminooxypentane-RANTES Induces CCR5 Internalization But Inhibits Recycling: A Novel Inhibitory Mechanisms Of HIV... J. Ex. Med., 187:1215-1224 | |
| | | Mackay, C.R. (1996). Chemokine Receptors And T Cell Chemotaxis. J. Exp. Med., 84:799-802 | |
| | | Maddon, P.J., et al. (1986). The T4 Gene Encodes The AIDS Virus Receptor And Is Expressed In The Immune System And The Brain. Cell, 47:333-348 | |
| | | Markosyan, R.M., et al. (2002). The Mechanism Of Inhibition Of HIV-1 Entry Env-Mediated Cell-Cell Fusion By Recombinant Cores Of gp41 Ectodomain. Virology, 302:174-184 | |
| | | McKnight, A.D., et al. (1997). Inhibition Of Human Immunodeficiency Virus Fusion By A Monoclonal Antibody To A Coreceptor (CXCR4) Is Both Cell Type... J. Virol., 71:1692-1696 | |
| | | Mellors, J.W. (1996). Closing In On Human Immunodeficiency Virus-1. Nature Medicine, 2(3):274-275 | |
| | | Mohan, P., et al. (1992). Sulfonic Acid Polymers As A New Class Of Human Immunodeficiency Virus Inhibitors. Antiviral Res., 18:139-150 | |
| | | Moser, B., et al. (1993). Interleukin-8 Antagonists Generated By N-Terminal Modification. J. Biol. Chem., 268:7125-7128 | |

| | |
|--------------------|----------------------------|
| Examiner Signature | Date Considered 11/12/2007 |
|--------------------|----------------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|--------------------------|-------------------|------------------------|----------|
| Substitute for form 1449/PTO | | Complete if Known | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 | | |
| | | Filing Date | July 12, 2001 | | |
| | | First Named Inventor | G.P. Allaway | | |
| | | Art Unit | 1648 | | |
| | | Examiner Name | Jeffery S. Parkin | | |
| Sheet | 23 | of | 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| ✓ | | Mosier, D.E. (1990). Immunodeficient Mice Xenografted With Human Lymphoid Cells: New Models For In-Vivo Studies Of Human Immunobiology And... J. Clin. Immuno., 10(4):185-191 | |
| | | Nagasawa, et al. (1994). Molecular Cloning And Structure Of A Pre-B-Cell Growth-Stimulating Factor. Proc. Natl. Acad. Sci., 91:2305-2309 | |
| | | Nagashima, K.A., et al. (2001). Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 And T-20 Are Potently Synergistic In Blocking... J. Infect. Dis., 183:1121-1125 | |
| | | Nakano, T., et al. (1995). Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca ²⁺ mobilizing growth.... J. Biol. Chem., 270(11):5702-5705 | |
| | | Neote, et al. (1993). Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell, 72:415-425 | |
| | | Oberg, B and Vrang, L. (1990). Screening for new agents. Eur. J. Clin. Microbiol. Infect. Dis., 9(7):466-471 | |
| | | Oberlin, E., et al. (1996). The CXC Chemokine SDF-1 is the Ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1. Nature, 382: 833-835 | |
| | | Oellerich, M., (1984). Enzyme-Immunoassay: A Review. J. Clin. Chem. Clin. Biochem., 22(12):895-904 | |
| | | Olson, et al., (1999). Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding and CC-chemokine Activity of Monoclonal... J. Virol., 73:4145-4155 | |
| | | Opperman, (2004). Chemokine Receptor CCR5: Insights Into Structure, Function, And Regulation. Cell. Signal., 16:1201-1210 | |

| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 11/12/2007 |
|--------------------|--|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 24 of 47 | Attorney Docket Number | 43966-CB | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | Parren, et al. (2001). Antibody Protects Macaques Against Vaginal Challenge With A Pathogenic R5 Simian/Human Immunodeficiency Virus At Serum.... J. Virol., 75:8340-8347 | |
| | | Partidos, C., et al. (1992). The Effect Of Orientation Of Epitopes On The Immunogenicity Of Chimeric Synthetic Peptides Representing... Molecular Immunology, 29(5):651-658 | |
| | | Poignard, P., et al. (1999). Neutralizing Antibodies Have Limited Effects On The Control Of Established HIV-1 Infection In-Vivo. Immunity, 10:431-438 | |
| | | Posner, M.R., et al. (1993). Neutralization Of HIV-1 By F105, A Human Monoclonal Antibody To The CD4 Binding Site Of gp120. J. Acq. Immune Defic. Synd., 6:7-14 | |
| | | Power, et al. (1995). Molecular Cloning And Functional Expression Of A Novel CC Chemokine Receptor Cdna From A Human Basophilic Cell Line. J. Biol. Chem., 270:1811-1815 | |
| | | Proudfoot, et al. (1996). Extension Of Recombinant Human RANTES By The Retention Of The Initiating Methionine Produces A Potent Antagonist. J. Biol. Chem., 271:2599-2603 | |
| | | Proudfoot, et al. (1999). Chemokine Receptors: Future Therapeutic Targets For HIV. Biochem. Pharmacol., 57:451-463 | |
| | | Proudfoot, et al. (2000). The Strategy Of Blocking The Chemokine System To Combat Disease. Immunol. Rev., 177:246-256 | |
| | | Queen, et al. (1989). A Humanized Antibody That Binds To The Interleukin 2 Receptor. Proc. Natl. Acad. Sci, 86:10029-10033 | |
| | | Rabut, G.E., et al. (1991). Alanine Substitutions Of Polar And Nonpolar Residues In The Amino-Terminal Domain Of CCR5 Differently Impair Entry Of.... J. Virol., 72:3464-3468 | |

| | |
|--------------------|----------------------------|
| Examiner Signature | Date Considered 11/12/2007 |
|--------------------|----------------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|--------------------------|-------------------|------------------------|----------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete If Known | | | |
| | | Application Number | 09/904,356 | | |
| | | Filing Date | July 12, 2001 | | |
| | | First Named Inventor | G.P. Allaway | | |
| | | Art Unit | 1648 | | |
| | | Examiner Name | Jeffery S. Parkin | | |
| Sheet | 25 | of | 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | Raport, C.J., et al. (1996). Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES,... J. Biol. Chem., 271:1761-1766 | |
| | | Raport, C.J., et al. (1996). New Members Of The Chemokine Receptor Gene Family. Journal of Leukocyte Biology, 59:18-23 | |
| | | Raport, C.J., et al. (1996). AAC50598 submitted to NCBI on April 12, 1996 (CC Chemokine Receptor 5 sequence) | |
| | | Richman, D.D. (1996). Antiretroviral Drug-Resistance: Mechanisms, Pathogenesis, Clinical Significance. Antivir. Chemother., 4:383-395 | |
| | | Rodriguez, G., et al. (1995). Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cel Surface Heparin Sulfate Proteoglycans... J. Virol., 69:2233-2239 | |
| | | Rucker, et al. (1996). Regions In Beta-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity. Cell, 87:437-446 | |
| | | Ruffing, et al. (1998). CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells. Cell. Immunol., 160:160-168 | |
| | | Rudikoff, et al. (1982). Single Amino Acid Substitution Altering Antigen-Binding Specificity. Proc. Natl. Acad. Sci., 79:1979-1983 | |
| | | Samson, M., et al. (1996). Molecular Cloning And Functional Expression Of A New Human CC-Chemokine Receptor Gene. Biochem., 35:3362-3367 | |
| | Sandberg, J. (1995). Developmental Pharmacology And Toxicology Of Anti-HIV Therapeutic Agents: Dideoxynucleosides. FASEB J., 9:1157-1163 | | |

| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 11/12/2007 |
|--------------------|--|-----------------|------------|



*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance, and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|--------------------------|-------------------|------------------------|----------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete If Known | | | |
| | | Application Number | 09/904,356 | | |
| | | Filing Date | July 12, 2001 | | |
| | | First Named Inventor | G.P. Allaway | | |
| | | Art Unit | 1648 | | |
| | | Examiner Name | Jeffery S. Parkin | | |
| Sheet | 26 | of | 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---|---|---|---|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|  | | Sato, et al. (1992). Anti-Cd7 Reagents Inhibit HIV-1 Induced Syncytium Formation. International Conference on AIDS, 81. PA5 PoA 2017 | |
| | | Sato, et al. (1994). Identification Of CD7 Glycoprotein As An Accessory Molecule In HIV-1 Mediated Syncytium Formation And Cell Free Infection. J. Immunol., 152:5142-5152 | |
| | | Sato, et al. (1995). A Simple And Rapid Method For Preliminary Evaluation Of In Vivo Efficacy Of Anti-HIV Compounds In Mice. Antivir. Res., 27:151-163 | |
| | | Scarlatti, et al. (1997). In Vivo Evolution Of HIV-1 Co-Receptor Usage And Sensitivity To Chemokine-Mediated Suppression. Nature Medicine, 3(11):1259-1265 | |
| | | Schanberg, et al. (1995). Characterization Of Human CD7 Transgenic Mice. J. of Immunol., 155:2407-2418 | |
| | | Schols, D., et al. (1990). Dextran sulfate and other oyanionic anti-HIV compounds specifically interact with the viral gp120 Glycoprotein Expressed... Virology, 175:556-561 | |
| | | Schols, D., et al. (1991). Selective Inhibitory Activity Of Polyhydroxycarboxylates Derived From Phenolic Compounds Against Human... J. Acq. Immune Defic. Synd., 4:677-685 | |
| | | Schols, D., et al. (1999). CD26-Processed RANTES(3-68), But Not Intact RANTES, Has Potent Anti-HIV-1 Activity. Antiviral Res., 30:175-187 | |
| | | Simmons, G., et al. (1997). Potent Inhibition Of HIV-1 Infectivity In Macropages And Lymphocytes By A Novel CCR5 Antagonist. Science, 276:276-279 | |
| |  | | Sommerfelt, M.A., et al. (1995). Intercellular Adhesion Molecule 3, A Candidate Human Immunodeficiency Virus Type 1 Co-Receptor On Lymphoid... J. Gen. Virol., 76:1345-1352 |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 11/12/2007 |
|--------------------|---|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|------------------------|--------------------------|-------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete If Known | |
| | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 27 of 47 | Attorney Docket Number | 43966-CB | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| J | | Steinberger, P., et al. (2000). Generation And Characterization Of A Recombinant Human CCR5-Specific Antibody. J. Biol. Chem., 275:36073-36078 | |
| | | Stewart, G.J. (1997). Increased Frequency Of CCR-5Δ32 Heterozygotes Among Long-Term Non-Progressors With HIV-1 Infection. AIDS, 11:1833-1838 | |
| | | Strizki, J.M., et al. (1997). A Monoclonal Antibody (12G5) Directed Against CXCR4 Inhibits Infection With The Dual-Tropic Human Immunodeficiency... J. Virol., 71:5678-5683 | |
| | | Su, et al. (1996). Preparation Of Specific Polyclonal Antibodies To A C-C Chemokine Receptor, CCR1, And Determination Of CCR1 Expression On... J. Leukos. Biol., 60:658-666 | |
| | | Thali, M., et al. (1992). Cooperativity Of Neutralizing Antibodies Directed Against The VS And CD4 Binding Regions Of The Human... J. Acq. Immune. Defic. Synd., 5:591-599 | |
| | | Tilley, S.A., et al. (1991). Potent Neutralization Of HIV-1 By Human And Chimpanzee Monoclonal Antibodies Directed Against Three... Sixieme Colloque Des Cent Gardes., 211-216 | |
| | | Tremblay, et al. (2000). Strong In Vitro Synergy Observed Between The Fusion... February 7th, 2000 Conference on Retroviruses and Opportunistic Infections, abstract 500 | |
| | | Tremblay, et al. (1999). Strong In Vitro Synergy Between The Fusion Inhibitor T-20 And The CXCR4 Blocker... Journal of Acquired Immune Deficiency Syndromes, 25(2):99-102 | |
| | | Trkola, A., et al. (2001). Potent, Broad-Spectrum Inhibition Of Human Immunodeficiency Virus Type 1 By The CCR5 Monoclonal Antibody PRO 140. J. Virol., 75:579-588 | |
| | | Trkola, A., et al. (1999). Cross-Clade Neutralization Of Primary Isolates Of Human Immunodeficiency Virus Type 1 By Human Monoclonal Antibodies... J. Virol., 73(5):4145-4155 | |

| | | | |
|--------------------|--|-----------------|-----------|
| Examiner Signature | | Date Considered | h/12/2007 |
|--------------------|--|-----------------|-----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 28 of 47 | Attorney Docket Number | 43966-CB | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| ✓ | | Trkola, A., et al. (1996). CD-4 Dependent, Antibody Sensitive Interactions Between HIV-1 And Its Co-Receptor CCR-5. Nature, 384:184-187 | |
| | | Trkola, A., et al. (1998). Neutralization Sensitivity Of Human Immunodeficiency Virus Type 1 Primary Isolates To Antibodies And CD40 based Reagents... J. Virol., 72:1876-1885 | |
| | | Tulp, W.R., et al. (1992). Crystal Structures Of Two Mutant Nerraminidase-Antibody Complexes With Amino Acid Substitutions In The Interface. J. Mol. Biol., 227:149-159 | |
| | | Valentin, et al. (1990). The Leukocyte Adhesion Glycoprotein CD18 Participates In HIV Induced Syncytia Formation In Monocytoid And T Cells. J. of Immunology, 144:934-937 | |
| | | Valenzuela, A., et al. (1997). Neutralizing Antibodies Against The V3 Loop Of Human Immunodeficiency Virus Type 1 Block The CD4-Dependent And... J. Virol., 71(11):8289-8298 | |
| | | Vijh-Warrier, S., Pinter, A., Honnen, W.J., and Tilley, S.A. (1996). Synergistic Neutralization Of Human Immunodeficiency Virus Type 1 By A... J. Virol., 70:4466-4473 | |
| | | Vila-Coro, et al. (2000). HIV-1 Infection Through The CCR5 Receptor Is Blocked By Receptor Dimerization. Proc. Natl. Acad. Sci., 97(7):3388-3393 | |
| | | Vita, C., et al. (1999). Rational Engineering Of A Mini-Protein That Reproduces The Core Of The CD4 Site Interacting With HIV-1... Proc. Natl. Acad. Sci. 96:13091-13096 | |
| | | Wang, et al. (1994). Deletion Of T Lymphocytes In Human CD4 Transgenic Mice Induced By HIV-gp120 and gp120-Specific Antibodies From AIDS... Eur. J. Immunol., 24:1553-1557 | |
| ✓ | | Wells, T.N.C., et al. (1996). Selectivity And Antagonism Of Chemokine Receptors. Journal of Leukocyte Biology, 59:53-60 | |

| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 11/12/2007 |
|--------------------|--|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|--------------------------|-------------------|------------------------|----------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete If Known | | | |
| | | Application Number | 09/904,356 | | |
| | | Filing Date | July 12, 2001 | | |
| | | First Named Inventor | G.P. Allaway | | |
| | | Art Unit | 1648 | | |
| | | Examiner Name | Jeffery S. Parkin | | |
| Sheet | 29 | of | 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| ✓ | | Wild, C., et al. (1992). A Synthetic Peptide Inhibitor Of Human Immunodeficiency Virus Replication: Correlation Between Solution... Proc. Natl. Acad. Sci., 89:10537-10541 | |
| | | Wild, C., et al. (1993). A synthetic peptide from HIV-1 Gp41 Is A Potent Inhibitor Of Virus Mediated Cell-Cell Fusion. AIDS Res. Humn. Retroviruses, 9:1051-1053 | |
| | | Wild, C., et al. (1994). Peptides Corresponding To A Predictive Alpha-Helical Domain Of Human Immunodeficiency Virus Type 1 gp41 Are... Proc. Natl. Acad. Sci., 91:9770-9774 | |
| | | Wild, C., et al. (1995). The Inhibitory Activity Of An HIV Type 1 Peptide Correlates With Its Ability To Interact With A Leucine... AIDS Res. Hum. Retroviruses, 11:323-325 | |
| | | Wu, et al. (1997). CCR5 Levels And Expression Pattern Correlate With Infectability By Macrophagetropic HIV-1 In Vitro. J. Exp. Med., 185(9):1681-1691 | |
| | | Wu, et al. (1997). Interaction Of Chemokine Receptor CCR5 With Its Ligands: Multiple Domains For HIV-1 gp120 Binding And A Single Domain... J. Exper. Med., 186(8):1373-1381 | |
| | | Wu, L., et al. (1996). CD4-Induced Interaction Of Primary HIV-1 gpl20 Glycoproteins With The Chemokine Receptor CCR-5. Nature, 384:179-183 | |
| | | Yamagami, et al. (1994). cDNA Cloning And Functional Expression Of Human Monocyte Chemoattractant Protein 1 Receptor. Biochem. Biophys. Res. Commun., 212:1156-1162 | |
| | | Yarchoan, R. and Broder, S. (1992). Correlations Between The In Vitro And The In Vivo Activity Of Anti-HIV Agents: Implications For Future... J. Enzyme Inhibit., 6:99-11 | |
| ✓ | | Ylisastigui, L., et al. (1998). Synthetic Full Length And Truncated RANTES Inhibit HIV-1 Infection Or Primary Macrophages. AIDS, 12:977-984 | |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 11/12/2007 |
|--------------------|---|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|--------------------------|-------------------|------------------------|----------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 09/904,356 | | |
| | | Filing Date | July 12, 2001 | | |
| | | First Named Inventor | G.P. Allaway | | |
| | | Art Unit | 1648 | | |
| | | Examiner Name | Jeffery S. Parkin | | |
| Sheet | 30 | of | 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| ✓ | | Zhang, Y.J., et al. (1994). Structure / Activity Analysis Of Human Monocyte Chemoattractant Protein-1 (MCP-1) By Mutagenesis. J. Biol. Chem., 269:15918-15924 | |
| | | July 16, 1998 Notice of Acceptance in connection with Australian Application No. 14387/95 | |
| | | November 27, 1996 Examiner's First Report in connection with Australian Application No. 14387/95 | |
| | | July 5, 2000 Notice of Acceptance in connection with Australian Application No. 62690/96 | |
| | | November 10, 1998 Examiner's First Report in connection with Australian Application No. 62690/96 | |
| | | September 14, 2006 Official Action in connection with Canadian Application No. 2,224,003 | |
| | | September 11, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3 | |
| | | March 8, 2006 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3 | |
| | | February 24, 2005 Provision of a Copy of the Minutes in accordance with Rule 76(4) EPC in connection with European Application No. 96 921 473.3 | |
| | | February 24, 2005 Decision to Refuse a European Patent Application in connection with European Application No. 96 921 473.3 | |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 11/12/2007 |
|--------------------|---|-----------------|------------|











*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|--------------------------|-------------------|------------------------|----------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 09/904,356 | | |
| | | Filing Date | July 12, 2001 | | |
| | | First Named Inventor | G.P. Allaway | | |
| | | Art Unit | 1648 | | |
| | | Examiner Name | Jeffery S. Parkin | | |
| Sheet | 31 | of | 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|  | | August 30, 2004 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3 | |
|  | | December 19, 2002 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3 | |
|  | | July 6, 2001 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3 | |
|  | | December 20, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/973,601 | |
|  | | August 3, 1999 Advisory Action in connection with U.S. Application Serial No. 08/973,601 | |
|  | | March 25, 1999 Office Action in connection with U.S. Application Serial No. 08/973,601 | |
|  | | June 24, 1998 Office Action in connection with U.S. Application Serial No. 08/973,601 | |
|  | | January 11, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/412,284 | |
|  | | December 2, 2003 Final Office Action in connection with U.S. Application Serial No. 09/412,284 | |
|  | | February 3, 2003 Office Action in connection with U.S. Application Serial No. 09/412,284 | |

| | | | |
|--------------------|---|-----------------|-----------|
| Examiner Signature |  | Date Considered | 6/12/2007 |
|--------------------|---|-----------------|-----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|-------|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 32 | of 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| J | | April 8, 2002 Advisory Action in connection with U.S. Application Serial No. 09/412,284 | |
| | | September 11, 2001 Final Office Action in connection with U.S. Application Serial No. 09/412,284 | |
| | | December 19, 2000 Office Action in connection with U.S. Application Serial No. 09/412,284 | |
| | | April 18, 2007 Office Action in connection with U.S. Application Serial No. 11/258,963 | |
| | | December 26, 2006 Office Action in connection with U.S. Application Serial No. 11/258,963 | |
| | | February 8, 2007 Office Action in connection with U.S. Application Serial No. 09/904,356 | |
| | | May 2, 2006 Final Office Action in connection with U.S. Application Serial No. 09/904,356 | |
| | | October 12, 2005 Office Action in connection with U.S. Application Serial No. 09/904,356 | |
| | | July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/904,356 | |
| | | November 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/904,356 | |

| | | | |
|--------------------|--|-----------------|-----------|
| Examiner Signature | | Date Considered | 4/12/2007 |
|--------------------|--|-----------------|-----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|-------|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 33 | of 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| J | | July 1, 2003 Office Action in connection with U.S. Application Serial No. 09/904,356 | |
| | | September 29, 2003 Advisory Action in connection with U.S. Application Serial No. 09/118,415 | |
| | | January 28, 2003 Final Office Action in connection with U.S. Application Serial No. 09/118,415 | |
| | | April 9, 2002 Office Action in connection with U.S. Application Serial No. 09/118,415 | |
| | | August 14, 2001 Advisory Action in connection with U.S. Application Serial No. 09/118,415 | |
| | | November 24, 2000 Final Office Action in connection with U.S. Application Serial No. 09/118,415 | |
| | | February 11, 2000 Office Action in connection with U.S. Application Serial No. 09/118,415 | |
| | | August 3, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062 | |
| | | July 17, 2006 Notice of Allowability in connection with U.S. Application Serial No. 09/891,062 | |
| | | May 18, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062 | |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 11/12/2001 |
|--------------------|---|-----------------|------------|


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|--------------------------|-------------------|------------------------|----------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 09/904,356 | | |
| | | Filing Date | July 12, 2001 | | |
| | | First Named Inventor | G.P. Allaway | | |
| | | Art Unit | 1648 | | |
| | | Examiner Name | Jeffery S. Parkin | | |
| Sheet | 34 | of | 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|--|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|  | | August 8, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062 | |
| | | March 21, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062 | |
| | | May 28, 2004 Advisory Action in connection with U.S. Application Serial No. 09/891,062 | |
| | | September 24, 2003 Final Office Action in connection with U.S. Application Serial No. 09/891,062 | |
| | | December 18, 2002 Office Action in connection with U.S. Application Serial No. 09/891,062 | |
| | | April 30, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 11/544,346 | |
| | | March 3, 1997 Office Action in connection with U.S. Application Serial No. 08/627,684 | |
| | | June 23, 1997 Office Action in connection with U.S. Application Serial No. 08/663,616 | |
| | | March 13, 1997 Office Action in connection with U.S. Application Serial No. 08/673,682 | |
| | | November 28, 2000 Notice of Acceptance in connection with Australian Application No. 26074/97 | |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 11/12/2007 |
|--------------------|---|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|-------|--------------------------|-------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 35 | of 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | July 13, 1999 Examiner's First Report in connection with Australian Application No. 26074/97 | |
| | | October 23, 2006 Official Action in connection with Canadian Application No. 2,250,829 | |
| | | May 27, 2005 Official Action in connection with Canadian Application No. 2,250,829 | |
| | | May 4, 2007 Summons to Attend Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 97917856.3 | |
| | | January 27, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3 | |
| | | October 21, 2005 Communication Pursuant to Article 115(2) EPC in connection with European Application No. 97917856.3 | |
| | | April 1, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3 | |
| | | August 5, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3 | |
| | | January 27, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3 | |
| | | May 9, 2003 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3 | |

| | |
|--------------------|----------------------------------|
| Examiner Signature | Date Considered <u>h/12/2007</u> |
|--------------------|----------------------------------|

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | | |
|---|----|--------------------------|-------------------|------------------------|----------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 09/904,356 | | |
| | | Filing Date | July 12, 2001 | | |
| | | First Named Inventor | G.P. Allaway | | |
| | | Art Unit | 1648 | | |
| | | Examiner Name | Jeffery S. Parkin | | |
| Sheet | 36 | of | 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | March 6, 2002 Search Report Communication in connection with European Application No. 97917856.3 | |
| | | February 27, 2007 Notification of Reasons for Rejection in connection with Japanese Application No. 535610/97 | |
| | | May 19, 2006 Examiner's First Report in connection with Australian Application No. 2004233505 | |
| | | July 26, 2004 Notice of Acceptance in connection with Australian Application No. 35106/01 | |
| | | July 5, 2004 Examiner's Second Report in connection with Australian Application No. 35106/01 | |
| | | November 1, 2002 Examiner's First Report in connection with Australian Application No. 35106/01 | |
| | | December 4, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823 | |
| | | January 16, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823 | |
| | | September 26, 2000 Advisory Action in connection with U.S. Application Serial No. 08/831,823 | |
| | | April 11, 2000 Final Office Action in connection with U.S. Application Serial No. 08/831,823 | |

| | | | |
|-----------------------|--|--------------------|-----------|
| Examiner Signature | | Date Considered | 7/12/2007 |
|-----------------------|--|--------------------|-----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|--------------------------|-------------------|------------------------|----------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 09/904,356 | | |
| | | Filing Date | July 12, 2001 | | |
| | | First Named Inventor | G.P. Allaway | | |
| | | Art Unit | 1648 | | |
| | | Examiner Name | Jeffery S. Parkin | | |
| Sheet | 37 | of | 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | July 21, 1999 Final Office Action in connection with U.S. Application Serial No. 08/831,823 | |
| | | December 21, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823 | |
| | | August 17, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823 | |
| | | June 15, 2006 Final Office Action in connection with U.S. Application Serial No. 09/888,938 | |
| | | September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938 | |
| | | September 7, 2005 Office action in connection with U.S. Application Serial No. 09/888,938 | |
| | | August 4, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938 | |
| | | May 5, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938 | |
| | | June 22, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/876,078 | |
| | December 21, 1998 Final Office Action in connection with U.S. Application Serial No. 08/876,078 | | |

| | | | |
|--------------------|--|-----------------|-----------|
| Examiner Signature | | Date Considered | 1/12/2007 |
|--------------------|--|-----------------|-----------|

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|-------|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 38 | of 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | March 23, 1998 Office Action in connection with U.S. Application Serial No. 08/876,078 | |
| | | June 16, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6 | |
| | | June 17, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6 | |
| | | October 17, 2006 Final Office Action in connection with U.S. Application Serial No. 09/460,216 | |
| | | February 3, 2006 Office Action in connection with U.S. Application Serial No. 09/460,216 | |
| | | July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/460,216 | |
| | | February 09, 2005 Final Office Action in connection with U.S. Application Serial No. 09/460,216 | |
| | | September 26, 2003 Advisory Action in connection with U.S. Application Serial No. 09/460,216 | |
| | | February 27, 2003 Final Office Action in connection with U.S. Application Serial No. 09/460,216 | |
| | | October 2, 2001 Office Action in connection with U.S. Application Serial No. 09/460,216 | |

| | |
|--------------------|----------------------------|
| Examiner Signature | Date Considered 11/12/2007 |
|--------------------|----------------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|--------------------------|-------------------|------------------------|----------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 09/904,356 | | |
| | | Filing Date | July 12, 2001 | | |
| | | First Named Inventor | G.P. Allaway | | |
| | | Art Unit | 1648 | | |
| | | Examiner Name | Jeffery S. Parkin | | |
| Sheet | 39 | of | 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | September 9, 2002 Notice of Acceptance in connection with Australian Application No. 81426/98 | |
| | | February 27, 2002 Examiner's Second Report in connection with Australian Application No. 81426/98 | |
| | | February 21, 2001 Examiner's First Report in connection with Australian Application No. 81426/98 | |
| | | February 4, 1997 Office Action in connection with U.S. Application Serial No. 08/665,090 | |
| | | August 29, 2000 Notice of Allowance and Allowability in connection with 08/874,618 | |
| | | November 19, 1999 Office Action in connection with U.S. Application Serial No. 08/874,618 | |
| | | May 24, 1999 Final Office Action in connection with U.S. Application Serial No. 08/874,618 | |
| | | September 2, 1998 Office Action in connection with U.S. Application Serial No. 08/874,618 | |
| | | December 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/724,105 | |
| | | March 23, 2005 Office Action in connection with U.S. Application Serial No. 09/724,105 | |

| | | | |
|-----------------------|--|--------------------|------------|
| Examiner Signature | | Date Considered | 11/12/2007 |
|-----------------------|--|--------------------|------------|

*EXAMINER: Initial preference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|----------|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Attorney Docket Number | 43966-CB | | |
| Sheet | 40 | of | 47 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | September 23, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105 | |
| | | May 19, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105 | |
| | | December 19, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497 | |
| | | August 8, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497 | |
| | | May 29, 2001 Notice of Acceptance in connection with Australian Application No. 34026/97 | |
| | | September 28, 1999 Examiner's First Report in connection with Australian Application No. 34026/97 | |
| | | November 10, 2006 Official Action in connection with Canadian Application No. 2,257,991 | |
| | | May 23, 2005 Communications Pursuant to Article 96(2) EPC in connection with European Application No. 97 930 120.7 | |
| | | November 17, 2004 Communication of partial European search report under Rule 45 EPC in connection with European Application No. 97 930 120.7 | |
| | September 9, 2004 Communication of partial European search report under Rule 46(1) EPC in connection with European Application No. 97 930 120.7 | | |

| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 11/12/2007 |
|--------------------|--|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|-------|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 41 | of 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| J | | October 17, 2006 Notification of Reasons for Rejection in connection with Japanese Application No. 501895/98 (English translation) | |
| | | April 5, 2004 Notice of Acceptance in connection with Australian Application No. 21996/00 | |
| | | February 5, 2003 Examiner's First Report in connection with Australian Application No. 21996/00 | |
| | | March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205164 | |
| | | March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205165 | |
| | | March 1, 2006 Communication under Rule 51(4) EPC in connection with European Application No. 99 966 466.7 | |
| | | January 10, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 99 966 466.7 | |
| | | October 14, 2004 Communication Pursuant to Article 96(1) and Rule 51(1) EPC in connection with European Application No. 99 966 466.7 | |
| | | January 18, 2007 Office communication in connection with Mexican Application No. 1006097 | |
| QV | | October 13, 2005 Office communication in connection with Mexican Application No. 1006097 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
| | 11/12/2007 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 42











of

47

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 09/904,356 |
| Filing Date | July 12, 2001 |
| First Named Inventor | G.P. Allaway |
| Art Unit | 1648 |
| Examiner Name | Jeffery S. Parkin |
| Attorney Docket Number | 43966-CB |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---|--------------------------|---|----------------|
|  | | February 6, 2007 Notice of Allowability in connection with U.S. Application Serial No. 09/464,902 | |
|  | | January 8, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/464,902 | |
|  | | April 19, 2006 Office Action in connection with U.S. Application Serial No. 09/464,902 | |
|  | | October 21, 2005 Office Action in connection with U.S. Application Serial No. 09/464,902 | |
|  | | June 15, 2005 Advisory Action in connection with U.S. Application Serial No. 09/464,902 | |
|  | | January 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/464,902 | |
|  | | April 2, 2004 Office Action in connection with U.S. Application Serial No. 09/464,902 | |
|  | | October 21, 2003 Office Action in connection with U.S. Application Serial No. 09/464,902 | |
|  | | September 25, 2001 Office Action in connection with U.S. Application Serial No. 09/464,902 | |
|  | | August 7, 2006 Office Action in connection with U.S. Application Serial No. 09/594,983 | |

| | | | |
|-----------------------|---|--------------------|------------|
| Examiner Signature |  | Date Considered | 11/12/2007 |
|-----------------------|---|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 43 of 47 | Attorney Docket Number | 43966-CB | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | March 24, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/594,983 | |
| | | July 11, 2005 Final Office Action in connection with U.S. Application Serial No. 09/594,983 | |
| | | August 25, 2004 Office Action in connection with U.S. Application Serial No. 09/594,983 | |
| | | September 23, 2003 Notice of Allowability in connection with U.S. Application Serial No. 09/594,983 | |
| | | December 3, 2002 Final Office Action in connection with U.S. Application Serial No. 09/594,983 | |
| | | March 13, 2002 Office Action in connection with U.S. Application Serial No. 09/594,983 | |
| | | September 28, 2001 Office Action in connection with U.S. Application Serial No. 09/594,983 | |
| | | December 19, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/763,545 | |
| | | July 26, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545 | |
| | | June 13, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545 | |

| | | |
|--------------------|-----------------|------------|
| Examiner Signature | Date Considered | 11/12/2007 |
|--------------------|-----------------|------------|

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 09/904,356 |
| Filing Date | July 12, 2001 |
| First Named Inventor | G.P. Allaway |
| Art Unit | 1648 |
| Examiner Name | Jeffery S. Parkin |
| Attorney Docket Number | 43966-CB |

Sheet 44

of 47

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| J | | February 16, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545 | |
| | | September 5, 2006 Communication in connection with U.S. Application Serial No. 10/371,483 | |
| | | August 21, 2006 Communication in connection with U.S. Application Serial No. 10/371,483 | |
| | | May 16, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/371,483 | |
| | | October 24, 2006 Office Action in connection with U.S. Application Serial No. 10/371,483 | |
| | | January 29, 2007 Examiner's First Report in connection Australian Application No. 2003217674 | |
| | | February 22, 2007 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 03 713 632.2 | |
| | | October 12, 2004 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 03 713 632.2 | |
| | | March 14, 2006 Examination Report in connection with New Zealand Application No. 534947 | |
| ✓ | | February 21, 2003 Official Action in connection with Russian Federation Application No. 2004128252/13(030609) (English Translation) | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
| | 11/12/2007 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|-------|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/904,356 |
| | | Filing Date | July 12, 2001 |
| | | First Named Inventor | G.P. Allaway |
| | | Art Unit | 1648 |
| | | Examiner Name | Jeffery S. Parkin |
| Sheet 45 | of 47 | Attorney Docket Number | 43966-CB |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| ✓ | | September 29, 2006 Grant of Patent in connection with Singaporean Application No. 200404610-8 | |
| | | August 7, 2002 Office Action in connection with U.S. Application Serial No. 09/663,219 | |
| | | January 5, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/912,824 | |
| | | January 26, 2005 Final Office Action in connection with U.S. Application Serial No. 09/912,824 | |
| | | April 20, 2004 Office Action in connection with U.S. Application Serial No. 09/912,824 | |
| | | July 2, 2003 Office Action in connection with U.S. Application Serial No. 09/912,824 | |
| | | July 3, 2006 Notice of Acceptance in connection with Australian Application No. 2001290925 | |
| | | June 28, 2005 Examiner's First Report in connection with Australian Application No. 2001290925 | |
| | | May 24, 2006 Supplementary European search report under Article 157(2)(a) EPC in connection with European Application No. 01970984.9 | |
| ✓ | | February 28, 2005 Formalities Examination in connection with European Application No. 01970984.9 | |

| | | |
|--------------------|-----------------|------------|
| Examiner Signature | Date Considered | 11/12/2007 |
|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 09/904,356 |
| Filing Date | July 12, 2001 |
| First Named Inventor | G.P. Allaway |
| Art Unit | 1648 |
| Examiner Name | Jeffery S. Parkin |
| Attorney Docket Number | 43966-CB |

Sheet 46

of 47

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---|-----------------------|---|----------------|
|  | | May 2, 2003 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 01970984.9 | |
| | | October 25, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/828,615 | |
| | | September 13, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615 | |
| | | March 2, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615 | |
| | | September 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/828,615 | |
| | | February 23, 2004 Office Action in connection with U.S. Application Serial No. 09/828,615 | |
| | | September 9, 2003 Advisory Action in connection with U.S. Application Serial No. 09/828,615 | |
| | | February 21, 2003 Final Office Action in connection with U.S. Application Serial No. 09/828,615 | |
| | | June 25, 2002 Office Action in connection with U.S. Application Serial No. 09/828,615 | |
|  | | June 9, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/116,797 | |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 11/12/2007 |
|--------------------|---|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**


(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 09/904,356 |
| Filing Date | July 12, 2001 |
| First Named Inventor | G.P. Allaway |
| Art Unit | 1648 |
| Examiner Name | Jeffery S. Parkin |
| Attorney Docket Number | 43966-CB |

Sheet 47 of 47

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---|--------------------------|---|----------------|
|  | | April 25, 2005 Final Office Action in connection with U.S. Application Serial No. 10/116,797 | |
| | | October 6, 2004 Office Action in connection with U.S. Application Serial No. 10/116, | |
| | | September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938 | |
| | | Bieniasz, P.D., et al. (1997). HIV-1 Induced Cell Fusion Is Mediated By Multiple Regions Within Both The Viral Envelope And The CCR5 Co-Receptor. EMBO, 16:2599-2609 | |
| | | Blanpain, C., et al. (1999). Multiple Charged And Aromatic Residues In CCR5... In High Affinity Binding Of Both Chemokines And HIV-1.... J. Biol. Chem., 274:34719-34727 | |
| | | February 15, 1996 Advisory Action in connection with U.S. Application Serial No. 08/169,311 | |
| | | September 13, 1995 Final Office Action in connection with U.S. Application Serial No. 08/169,311 | |
| | | November 23, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311 | |
| | | August 18, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311 | |
| | | | |

| | | | |
|-----------------------|---|--------------------|------------|
| Examiner Signature |  | Date Considered | 11/12/2007 |
|-----------------------|---|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.